Insight into the structural similarity between HIV protease and secreted aspartic protease-2 and binding mode analysis of HIV-Candida albicans inhibitors

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 28, Issue 5, 2013, Pages 936-943

  Calugi, Chiara ^a   Guarna, Antonio ^a   Trabocchi, Andrea ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Aspartic protease; Infectious disease; Molecular docking; Peptidomimetic; Virulence factor

Indexed keywords

ASPARTIC PROTEINASE; ASPARTIC PROTEINASE 2; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; UNCLASSIFIED DRUG;

ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENZYME BINDING; ENZYME CONFORMATION; ENZYME RELEASE; ENZYME STRUCTURE; ENZYME SUBSTRATE COMPLEX; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ALIGNMENT;

ASPARTIC ACID ENDOPEPTIDASES; BINDING SITES; CANDIDA ALBICANS; CRYSTALLOGRAPHY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; FUNGAL PROTEINS; HIV; HIV PROTEASE; HIV PROTEASE INHIBITORS; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84884276521     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2012.696245     Document Type: Article

References (36)

1. Rothenberg R, Woelfel M, Stoneburner R, Milberg J, Parker R, Truman B. Survival with the acquired immunodeficiency syndrome. Experience with 5833 cases in New York City. N Engl J Med 1987;317:1297-1302.
2. Schmidt-Westhausen A, Schiller RA, Pohle HD, Reichart PA. Oral Candida and Enterobacteriaceae in HIV-1 infection: Correlation with clinical candidiasis and antimycotic therapy. J Oral Pathol Med 1991;20:467-472.
3. Cataldo M, Tacconelli E, Sanguinetti M, Villa P, Fadda G, Cauda R. Highly active antiretroviral therapy (HAART) and probability of Candida vaginitis in HIV-infected patients. Trends Med Mycol 2003:165-169.
4. Hoegl L, Thoma-Greber E, Röcken M, Korting HC. HIV protease inhibitors influence the prevalence of oral candidosis in HIVinfected patients: A 2-year study. Mycoses 1998;41:321-325.
5. Korting HC, Schaller M, Eder G, Hamm G, Böhmer U, Hube B. Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients. Antimicrob Agents Chemother 1999;43:2038-2042.
6. Cassone A, De Bernardis F, Torosantucci A, Tacconelli E, Tumbarello M, Cauda R. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J Infect Dis 1999;180:448-453.
7. Schaller M, Schackert C, Korting HC, Januschke E, Hube B. Invasion of Candida albicans correlates with expression of secreted aspartic proteinases during experimental infection of human epidermis. J Invest Dermatol 2000;114:712-717.
8. Naglik JR, Challacombe SJ, Hube B. Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev 2003;67:400-28, table of contents
9. De Bernardis F, Cassone A, Sturtevant J, Calderone R. Expression of Candida albicans SAP1 and SAP2 in experimental vaginitis. Infect Immun 1995;63:1887-1892.
10. Naglik JR, Newport G, White TC, Fernandes-Naglik LL, Greenspan JS, Greenspan D et al. In vivo analysis of secreted aspartyl proteinase expression in human oral candidiasis. Infect Immun 1999;67:2482-2490.
11. Schaller M, Januschke E, Schackert C, Woerle B, Korting HC. Different isoforms of secreted aspartyl proteinases (Sap) are expressed by Candida albicans during oral and cutaneous candidosis in vivo. J Med Microbiol 2001;50:743-747.
12. Albrecht A, Felk A, Pichova I, Naglik JR, Schaller M, de Groot P et al. Glycosylphosphatidylinositol-anchored proteases of Candida albicans target proteins necessary for both cellular processes and host-pathogen interactions. J Biol Chem 2006;281:688-694.
13. Taylor BN, Hannemann H, Sehnal M, Biesemeier A, Schweizer A, Röllinghoff M et al. Induction of SAP7 correlates with virulence in an intravenous infection model of candidiasis but not in a vaginal infection model in mice. Infect Immun 2005;73:7061-7063.
14. Cassone A, De Bernardis F, Mondello F, Ceddia T, Agatensi L. Evidence for a correlation between proteinase secretion and vulvovaginal candidosis. J Infect Dis 1987;156:777-783.
15. Gauwerky K, Borelli C, Korting HC. Targeting virulence: A new paradigm for antifungals. Drug Discov Today 2009;14:214-222.
16. Dostál J, Brynda J, Hrušková-Heidingsfeldová O, Pachl P, Pichová I, Rezácová P. The crystal structure of protease Sapp1p from Candida parapsilosis in complex with the HIV protease inhibitor ritonavir. J Enzyme Inhib Med Chem 2012;27:160-165.
17. Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modeling. Electrophoresis 1997;18:2714-2723.
18. ExPAsy Proteomics Server. http://www.expasy.org
19. Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 1997;267:727-748.
20. Korb O, Stützle T, Exner TE. Empirical scoring functions for advanced protein-ligand docking with PLANTS. J Chem Inf Model 2009;49:84-96.
21. DeLano WL. The PyMOL Molecular Graphics System. DeLano Scientific LLC, San Carlos, CA, USA. http://www.pymol.org.
22. Cutfield SM, Dodson EJ, Anderson BF, Moody PC, Marshall CJ, Sullivan PA et al. The crystal structure of a major secreted aspartic proteinase from Candida albicans in complexes with two inhibitors. Structure 1995;3:1261-1271.
23. Koelsch G, Tang J, Loy JA, Monod M, Jackson K, Foundling SI et al. Enzymic characteristics of secreted aspartic proteases of Candida albicans. Biochim Biophys Acta 2000;1480:117-131.
24. Roberts NA, Martin JA, Kinchington D, Broadhurst AV, Craig JC, Duncan IB et al. Rational design of peptide-based HIV proteinase inhibitors. Science 1990;248:358-361.
25. Pichová I, Pavlícková L, Dostál J, Dolejsí E, Hrusková- Heidingsfeldová O, Weber J et al. Secreted aspartic proteases of Candida albicans, Candida tropicalis, Candida parapsilosis and Candida lusitaniae. Inhibition with peptidomimetic inhibitors. Eur J Biochem 2001;268:2669-2677.
26. Kempf DJ, Marsh KC, Denissen JF, McDonald E, Vasavanonda S, Flentge CA et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci USA 1995;92:2484-2488.
27. Wlodawer A, Gustchina A. Structural and biochemical studies of retroviral proteases. Biochim Biophys Acta 2000;1477:16-34.
28. Blundell TL, Lapatto R, Wilderspin AF, Hemmings AM, Hobart PM, Danley DE et al. The 3-D structure of HIV-1 proteinase and the design of antiviral agents for the treatment of AIDS. Trends Biochem Sci 1990;15:425-430.
29. Gruber A, Speth C, Lukasser-Vogl E, Zangerle R, Borg-von Zepelin M, Dierich MP et al. Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro. Immunopharmacology 1999;41: 227-234.
30. Borg-von Zepelin M, Meyer I, Thomssen R, Würzner R, Sanglard D, Telenti A et al. HIV-Protease inhibitors reduce cell adherence of Candida albicans strains by inhibition of yeast secreted aspartic proteases. J Invest Dermatol 1999;113:747-751.
31. Gruber A, Berlit J, Speth C, Lass-Flörl C, Kofler G, Nagl M et al. Dissimilar attenuation of Candida albicans virulence properties by human immunodeficiency virus type 1 protease inhibitors. Immunobiology 1999;201:133-144.
32. EMBOSS Matcher - Pairwise Sequence Alignment from the EMBL-EBI tools website. http://www.ebi.ac.uk/Tools/psa/ emboss-matcher/
33. Abad-Zapatero C, Goldman R, Muchmore SW, Hutchins C, Stewart K, Navaza J et al. Structure of a secreted aspartic protease from C. albicans complexed with a potent inhibitor: implications for the design of antifungal agents. Protein Sci 1996;5: 640-652.
34. Tie Y, Kovalevsky AY, Boross P, Wang YF, Ghosh AK, Tozser J et al. Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir. Proteins 2007;67: 232-242.
35. Pranav Kumar SK, Kulkarni VM. Insights into the selective inhibition of Candida albicans secreted aspartyl protease: A docking analysis study. Bioorg Med Chem 2002;10: 1153-1170.
36. Behnen J, Köster H, Neudert G, Craan T, Heine A, Klebe G. Experimental and computational active site mapping as a starting point to fragment-based lead discovery. ChemMedChem 2012;7:248-261.